De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Hikma Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 3/6
De winst van Hikma Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -18.8%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks daalde met 2.4%. De inkomsten zijn groeide met een gemiddeld percentage van 6.3% per jaar. Het rendement op het eigen vermogen Hikma Pharmaceuticals bedraagt 12.6% en de nettomarge bedraagt 9.4%.
Belangrijke informatie
-18.8%
Groei van de winst
-16.9%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 14.1% |
Inkomstengroei | 6.3% |
Rendement op eigen vermogen | 12.6% |
Nettomarge | 9.4% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Opbrengsten en kosten
Hoe Hikma Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 3,017 | 285 | 651 | 146 |
31 Mar 24 | 2,946 | 238 | 642 | 148 |
31 Dec 23 | 2,875 | 190 | 632 | 149 |
30 Sep 23 | 2,803 | 168 | 619 | 144 |
30 Jun 23 | 2,731 | 146 | 606 | 139 |
31 Mar 23 | 2,624 | 167 | 604 | 142 |
31 Dec 22 | 2,517 | 188 | 601 | 144 |
30 Sep 22 | 2,534 | 267 | 593 | 149 |
30 Jun 22 | 2,550 | 346 | 585 | 153 |
31 Mar 22 | 2,552 | 384 | 573 | 148 |
31 Dec 21 | 2,553 | 421 | 561 | 143 |
30 Sep 21 | 2,489 | 444 | 535 | 139 |
30 Jun 21 | 2,425 | 467 | 509 | 134 |
31 Mar 21 | 2,383 | 449 | 508 | 136 |
31 Dec 20 | 2,341 | 431 | 506 | 137 |
30 Sep 20 | 2,317 | 472 | 503 | 134 |
30 Jun 20 | 2,292 | 513 | 500 | 130 |
31 Mar 20 | 2,250 | 500 | 494 | 128 |
31 Dec 19 | 2,207 | 486 | 487 | 126 |
30 Sep 19 | 2,173 | 424 | 481 | 128 |
30 Jun 19 | 2,138 | 361 | 475 | 129 |
31 Mar 19 | 2,104 | 322 | 471 | 124 |
31 Dec 18 | 2,070 | 282 | 467 | 118 |
30 Sep 18 | 2,045 | -262 | 464 | 110 |
30 Jun 18 | 2,020 | -806 | 460 | 102 |
31 Mar 18 | 1,978 | -824 | 467 | 109 |
31 Dec 17 | 1,936 | -843 | 474 | 115 |
30 Sep 17 | 1,950 | -338 | 462 | 122 |
30 Jun 17 | 1,963 | 166 | 450 | 129 |
31 Mar 17 | 1,957 | 161 | 440 | 128 |
31 Dec 16 | 1,950 | 155 | 429 | 126 |
30 Sep 16 | 1,782 | 166 | 411 | 100 |
30 Jun 16 | 1,613 | 176 | 392 | 73 |
31 Mar 16 | 1,527 | 214 | 372 | 55 |
31 Dec 15 | 1,440 | 252 | 352 | 36 |
30 Sep 15 | 1,450 | 248 | 346 | 46 |
30 Jun 15 | 1,460 | 243 | 339 | 56 |
31 Mar 15 | 1,475 | 261 | 342 | 56 |
31 Dec 14 | 1,489 | 278 | 345 | 55 |
30 Sep 14 | 1,477 | 293 | 339 | 46 |
30 Jun 14 | 1,465 | 308 | 333 | 37 |
31 Mar 14 | 1,415 | 260 | 322 | 34 |
31 Dec 13 | 1,365 | 212 | 311 | 31 |
Kwaliteitswinsten: HIK heeft een grote eenmalige verlies van $264.0M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.
Groeiende winstmarge: De huidige netto winstmarges (9.4%) HIK } zijn hoger dan vorig jaar (5.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van HIK is de afgelopen 5 jaar met 18.8% per jaar gedaald.
Versnelling van de groei: De winstgroei van HIK over het afgelopen jaar ( 95.2% ) overtreft het 5-jarig gemiddelde ( -18.8% per jaar).
Winst versus industrie: De winstgroei HIK over het afgelopen jaar ( 95.2% ) overtrof de Pharmaceuticals -sector 4.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 12.6% ) van HIK wordt als laag beschouwd.